| JKN465
|
Research Grade Gontivimab
|
1257358-38-5 |
95% |
None
|
| JKN464
|
Research Grade Golimumab
|
476181-74-5 |
95% |
None
|
| JKN463
|
Research Grade Gimsilumab
|
1648796-29-5 |
95% |
None
|
| JKN461
|
Research Grade Faricimab
|
1607793-29-2 |
95% |
None
|
| JKN460
|
Research Grade Etigilimab
|
2044984-83-8 |
95% |
None
|
| JKN459
|
Research Grade Enapotamab
|
1912423-61-0 |
95% |
None
|
| JKN458
|
Research Grade Cusatuzumab
|
1399546-01-0 |
95% |
None
|
| JKN457
|
Research Grade Clenoliximab
|
182912-58-9 |
95% |
None
|
| JKN456
|
Research Grade Cergutuzumab
|
1509916-03-3 |
95% |
None
|
| JKN455
|
Research Grade Cedelizumab
|
156586-90-2 |
95% |
None
|
鄂公网安备42011102005485号
鄂ICP备2024034540号
? 2023万利官网
